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Abstract
Background: Acute respiratory infections (ARI) are frequent in children and complications can occur in patients
with chronic diseases. We evaluated the frequency and impact of ARI and influenza-like illness (ILI) episodes on
disease activity, and the immunogenicity and safety of influenza vaccine in a cohort of juvenile idiopathic arthritis
(JIA) patients.
Methods: Surveillance of respiratory viruses was conducted in JIA patients during ARI season (March to August) in
two consecutive years: 2007 (61 patients) and 2008 (63 patients). Patients with ARI or ILI had respiratory samples
collected for virus detection by real time PCR. In 2008, 44 patients were immunized with influenza vaccine. JIA
activity index (ACRPed30) was assessed during both surveillance periods. Influenza hemagglutination inhibition
antibody titers were measured before and 30-40 days after vaccination.
Results: During the study period 105 ARI episodes were reported and 26.6% of them were ILI. Of 33 samples
collected, 60% were positive for at least one virus. Influenza and rhinovirus were the most frequently detected, in
30% of the samples. Of the 50 JIA flares observed, 20% were temporally associated to ARI. Influenza seroprotection
rates were higher than 70% (91-100%) for all strains, and seroconversion rates exceeded 40% (74-93%). In general,
response to influenza vaccine was not influenced by therapy or disease activity, but patients using anti-TNF alpha
drugs presented lower seroconversion to H1N1 strain. No significant differences were found in ACRPed30 after
vaccination and no patient reported ILI for 6 months after vaccination.
Conclusion: ARI episodes are relatively frequent in JIA patients and may have a role triggering JIA flares. Trivalent
split influenza vaccine seems to be immunogenic and safe in JIA patients.
Keywords: Acute respiratory infections, Respiratory viruses, Influenza-like illness, Influenza vaccine, Juvenile
idiopathic arthritis
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Background
Acute respiratory infections (ARI) are prevalent world-
wide and infections by influenza virus are particularly
responsible for morbidity and mortality among children
and other groups considered at high risk for complica-
tions from viral infections [1,2].
There have been no published studies on the preva-
lence of viral respiratory infections in juvenile idiopathic
arthritis (JIA) patients and it is not known if these
patients are at higher risk for severe influenza infections
as compared to healthy children. Few studies have sug-
gested ARI as trigger of JIA [3,4]. Available evidence
suggests that influenza vaccination is safe and immuno-
genic in children with JIA. However, it is not known if
influenza vaccination is actually protective against
influenza-like illness (ILI) [5-12].
The objectives of this study were to evaluate the fre-
quency of ARI and ILI in JIA patients and how they
affect disease activity, and to assess immunogenicity,
safety and efficacy of influenza vaccine in JIA patients
treated with potentially immunosuppressive drugs, in-
cluding anti-TNFα.
Methods
Study design and population
We performed a longitudinal, prospective surveillance
study of ARI and ILI episodes, and of influenza vaccin-
ation in a cohort of JIA patients, classified by the Inter-
national League Against Rheumatism (ILAR) criteria,
attending a tertiary Pediatric Rheumatology Clinic [13].
The surveillance occurred during the months of peak
occurrence of ARI in two consecutive years: March
through August 2007 (surveillance 1, SV1) and March
through August 2008 (surveillance 2, SV2). Of the
ninety eligible JIA patients, 61 participated of SV1
(15 patients lost follow up during SV1 and 14 pa-
tients were not able to attend regular visits due to
home distance from the hospital). Sixty-three pa-
tients participated in SV2 period: 55 of the 61 pa-
tients who participated on SV1, 7 new JIA patients
and 1 old patient that returned to follow up during
this period (Figure 1).
Influenza vaccine was offered between April and July
2008 to all JIA patients attending the clinic that agreed
to participate. Patients with at least one of the following
criteria were excluded from vaccination: presence
of systemic symptoms (fever, rash, vasculitis, hepato-
splenomegaly, serositis); vaccination with any other
vaccine in the previous month, allergy to components of
influenza vaccine, and previous history of Guillain-Barre
syndrome. Ten healthy children, between 3 and 18 years,
received the influenza vaccine in order to evaluate the
immunogenicity of that specific batch of the vaccine.
Routine clinical evaluations, including the Pediatric
American College of Rheumatology 30% (ACRPed30)
[14] were conducted during both surveillance periods
prior to and at 30, 90 and 180 days after influenza
vaccination.
JIA flares were defined as worsening by at least 40% in
two or more of the six criteria in the ACRPed index,
with simultaneous improvement of up to one criterion
above 30% [15], and were considered as related to ARI
or ILI if occurred up to 30 days after the ARI or ILI epi-
sodes. Disease activity was defined as presence of at least
one joint with active arthritis or any systemic sign or
symptom (fever, rash, vasculitis, hepatosplenomegaly,
serositis) [16].
The study protocol was approved by the Ethics Com-
mittee of the Hospital das Clínicas da Faculdade
de Medicina de Ribeirão Preto-USP (Process number
10542/2007) and the parents of all children and adoles-
cents involved in the study gave informed consent for
their participation.
Surveillance for ARI and ILI episodes
ARI episodes were defined by the presence of one or
more respiratory symptoms (rhinorrhea, sneezing, nasal
obstruction, hoarseness, stridor, cough, dyspnea, tachyp-
nea, chest retraction, wheezing or rhonchi). Cases of ILI
were defined by the presence of fever plus at least one
respiratory symptom (cough and/or sore throat) and one
constitutional symptom (headache, malaise, myalgia,
sweat or chills, or fatigue) [17,18]. Contacts with patients
were made by telephone every two to three weeks and
during their routine visits. Patients were also instructed
to contact our medical staff in case of any respiratory
symptom. Clinical assessment of disease activity, includ-
ing laboratory tests, was carried out following the clinic
routines. After the observation period, medical records
were analyzed retrospectively to identify possible
temporal associations, up to 30 days, between ARI/ILI
episodes and signs of worsening of the underlying
disease. During the two study periods, SV1 and SV2, pa-
tients with ARI and/or ILI had nasopharyngeal swabs
collected for viral detection within the first 72 hours of
symptoms, according to recommended procedures [19].
The attack rate was expressed as ARI episodes per
1,000 child-days at risk. A child-day was considered as
1 day of study for each child in the cohort. In calculating
attack rate, only at-risk child-days were included in the
denominator, with the removal of those days contained
within an ARI and the 3 subsequent days [18,20]
Detection of respiratory viruses
Nasopharyngeal swabs collected from both nostrils were
immersed in viral transport medium (VTM) and imme-
diately transported on ice to the Viral Pathogenesis
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Laboratory at the Virology Research Center, University
of São Paulo, School of Medicine of Ribeirão Preto. Sam-
ples were then frozen at -70°C until being tested by real-
time PCR for the presence of influenza A and B, respira-
tory syncytial virus (HRSV) A and B, metapneumovirus
(HMPV), parainfluenza virus (HPIV) 1 and 3, bocavirus
(HBov), adenovirus (HAdv), rhinovirus (HRV) and corona-
virus OC43 e 229E (HCov).
Nucleic acids were extracted from 200 μL of sample
using the QIAamp MinElute Virus Spin Kit (Qiagen,
Hilden, Germany) following the manufacturer’s instruc-
tions. Detection of respiratory viruses was performed by
real-time PCR (qPCR) using the TaqMan strategy
(Applied Biosystems) with specific primers and probes
(Additional file 1) [21-30] in a Thermocycler 7300 (Ap-
plied Biosystems). qPCR for the housekeeping β-actin
gene was done in all samples as internal control. qPCR
for HRSVA and B; HCoV OC43 and 229E; two sets of
HRV serotypes; and HAdv and HBoV were done in du-
plex format, whereas single qPCR with only one pair of
Figure 1 Study time-table describing surveillance for viral respiratory infections, influenza vaccination and follow-up after vaccination
period. *Surveillance for upper respiratory viruses occurred during two subsequent years, from March to August: 2007- surveillance 1; and 2008 –
surveillance 2. ** Influenza vaccine was offered between April and July 2008, during the surveillance 2 period. # Follow-up after vaccination:
period of six months after the vaccine. n = number of patients included in each period.
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primers per reaction was done for HMPVA, HMPVB,
influenza A, influenza B, HPIV1, HPIV3 and β-actin. For
RNA viruses (HRV, influenza, HPIV, HRSV, HMPV and
HCoV) reverse transcription was done prior to PCR
using Multiscribe reverse transcriptase (Applied Bio-
systems) with 1 μg of RNA, primed with random
hexamers, following the protocol proposed by the
manufacturer detailed in the Additional file 1.
Influenza vaccination
The trivalent split influenza vaccine containing A/
Solomon Islands/3/2006, H1N1; A/Brisbane/10/2007,
H3N2; B/Florida/4/2006, and B/Florida (Sanofi Pasteur
SA/Butantan Institute), recommended for use in the
Southern Hemisphere in 2008 [31] was given to patients
and healthy children between March and May 2008. Pa-
tients and healthy children older than 9 years received one
intramuscular dose of the vaccine (0.5 ml); and 3-8 and 1-
3 year-old patients received two doses of 0.5 ml and
0.25 ml, respectively, 4 weeks apart, following established
recommendations [32]. Local symptoms at the injection site
and systemic symptoms were recorded.
Influenza antibody titer determinations
Anti-influenza antibody titers were determined by
hemagglutination inhibition (HI) prior to and 30-40 days
post vaccination at the Respiratory Viruses Laboratory
in Evandro Chagas Institute according to a standard
WHO procedure [33].
Serum samples were stored at -70°C until testing,
when they were treated with receptor-destroying enzyme
and with turkey red blood cells to remove nonspecific
agglutinins. Serum samples were then tested by HI for
antibodies against the three antigens included in the vac-
cine. The working dilution (test dose) of each antigen
contained four HI units in 25 μl. Test doses were diluted
in phosphate-buffered saline and added to serial dilu-
tions of antiserum (1:1 to 1:1024). The HI titer was de-
termined as the reciprocal of the last serum dilution that
completely inhibited red blood cell agglutination.
The titer of a serum not showing any inhibition at di-
lution 1:1 was assigned a value of 5.
A 4-fold rise in titers or a rise in titer from <20 to ≥40
was considered a significant response to vaccination. HI
titers ≥40 are indicative of protection against infection.
The geometric mean titers (GMT) were calculated using
log-transformed titer values. A protection rate exceeding
70% of the vaccinated group, a seroconversion rate ex-
ceeding 40%, and a seroconversion factor exceeding 2.5
are considered as cut-off levels of vaccine immunogen-
icity, according to the guidelines of the European Com-
mittee for Proprietary Medicinal Products (CPMP) for
the assessment of influenza vaccines in adults [34,35].
Statistical methods
Statistical analysis was carried out using the SAS/STATW
system, version 9 (SAS Institute Inc., 2002).
To compare the frequency of episodes of ARI, ILI and
worsening of indices of disease activity between periods
of surveillance 1 and 2, and between vaccinated and un-
vaccinated patients the data were fitted in a zero-inflated
Poisson model [36]. A multiple model for comparison of
ARI and ILI episodes adjusted for other covariates: JIA
type of onset (oligoarticular, polyarticular or systemic),
gender, age (< 9 years old and ≥ 9 years old), disease ac-
tivity and use of immunosuppressive therapy were
performed.
The student t test was used to compare geometric
means of HI titers. Calculations were performed on log-
transformed values (base 10).
Fisher’s exact test was used to evaluate associations be-
tween the response rates to the 3 vaccine antigens and
patient groups with different therapeutic regimens
(methotrexate/leflunomide, TNF-α inhibitor), different
age-groups (< 9 yrs and ≥ 9 yrs), JIA onset type (oligo-
articular, polyarticular and systemic) and between pa-
tients with active disease. A logistic regression model
adjusted to these covariates was performed for evaluate
influence on seroconversion.
For comparison of variables related to disease activity
before and after vaccination, the nonparametric Friedman
test was used.
For all tests, a significance level of 5% was adopted.
Results
Frequency of ARI and ILI
Demographics and JIA clinical characteristics of the pa-
tients are summarized in Table 1.
During the two surveillance periods, 105 ARI episodes
were reported: 68 in 44 of 61 (72%) patients during the
SV1 and 37 in 26 of 63 (41%) patients during the SV2.
We evaluated the data of 9333 child-days in SV1 and
9639 child-days in SV2, 296 (3.1%) and 208 (2.1%) days
respectively were contained within an ARI (ARI mean
duration:5 days), and 204 and 111 days were subsequent
not-at-risk days, leaving 8833 and 9320 days at-risk
child-days (including the first day of each ARI) in SV1
and SV2 respectively. This gives an attack rate with 95%
confidence interval (95% CI) of 7.6 (5.9-9.8) and 3.9
(2.8-5.5) ARI per 1000 child-days in SV1 and SV2 re-
spectively. Twenty-eight of the 105 episodes (26.6%)
were characterized as ILI: 23 during SV1 and 5 during
SV2.
ARI and ILI episodes were significantly more frequent
in SV1 than in SV2 (p < 0,01), even when adjusting for
JIA type of onset, age (younger or older than 9 years),
disease activity, use of immunosuppressives or DMARDs
or administration of influenza vaccine.
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There was no significant difference (p = 0.1) in the
frequency of ARI episodes between vaccinated and
unvaccinated patients. However, ILI episodes were sig-
nificantly more common in unvaccinated patients
(p = 0.02), although this difference was not maintained
after adjusting for the other variables described above
(p = 0.96). Of 33 naso-pharyngeal samples collected dur-
ing the study, 20 (60.6%) were positive for at least one
respiratory virus and viral co-infections were detected in
20% of the positive samples (Table 2).
Considering SV1 and SV2, a total of 28 ILI episodes
were reported. Positive influenza samples were obtained
in 5/14 ILI episodes of SV1 (35%) and in 1/7 ILI epi-
sodes during SV2 (14%), in a patient included prior to
influenza vaccination. Although the most commonly
detected virus during ILI episodes was influenza,
detected in 7/28 (25%), HPIV (1 and 3) and HAdv were
detected in one ILI episode each (Table 2).
All patients with ARI and ILI had favorable outcomes,
except for one patient who developed acute otitis media
Table 1 Characteristics of JIA patients participating in the two periods of surveillance for acute respiratory infections
and in the phase of vaccination against influenza virus
SV 1 SV 2 Vaccination
Patients (n) 61 63 44
Age, mean (years) 10.7 10.9 11.0
ILAR categories n (%)
Oligoarthritis extended 8 (13.1) 12 (19) 9 (20.4)
Oligoarthritis persistent 12 (19.6) 11 (17.4) 11 (25)
Polyarticular RF - 20 (32.7) 19 (30.1) 12 (27.3)
Polyarticular RF+ 4 (6.5) 5 (7.9) 4 (9)
Systemic 13 (21.3) 13 (20.6) 7 (16)
Undifferentiated arthritis 4 (6.5) 3 (4.8) 1 (2.3)
Use of immunosuppressant, DMARDS or anti-TNF drugs, n (%) 34 (55.7) 43 (68.2) 31(70)
Use of corticosteroids, n (%) 5 (8.2) 5 (7.9) 6 (13.6)
(mean daily dose corticosteroids: mg/kg/day) 0.45 (0.05-1) 0.34 (0.1-0.5) 0.3 (0.1-0.6)
Active disease n (%) 21 (34.4) 25 (39.6) 25(57)
Surveillance for respiratory infections: from March to August 2007- surveillance 1 (SV1) and from March to August 2008 – surveillance 2 (SV2). ILAR: International
League of Associations for Rheumatology, RF: rheumatoid factor.
Table 2 Episodes of acute respiratory infections and influenza-like illness and virus identification during the
surveillance 1 and 2 periods in patients with JIA
SV 1 SV 2 p
Patients (n) 61 63
ARI episodes 68 37 <0.01*
ILI episodes (% of ARI) 23 (33,8) 5 (13,5) <0.01*
Samples collected 26 7
Positive samples - PCR (n) Flu A (4) Flu A (1)
Flu B (1) HRV (1)
HRV (2) HBov (1)
HPIV 1 (2) HRSVA + HMPV (1)
HPIV 3 (1)
HAdv (2)
HRSVA (1)
HRV + HAdv (2)
HRV + HCov (1)
N (%) of patients who received Flu Vaccine in the period 1 (1.5%) 44 (69.8%)
ARI: Acute respiratory infection, ILI: Influenza-like illness, Flu: Influenza virus, HRSV: respiratory syncytial virus A and B, HMPV: metapneumovirus, HPIV: parainfluenza
virus 1 and 3, HBov: bocavirus, HAdv: adenovirus, HRV: rhinovirus, HCov: coronavirus OC43 and 229E. SV1: Surveillance 1, from March to August 2007. SV2:
Surveillance 2, from March to August 2008, influenza vaccine was given in this period.* Poisson’s test.
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and pneumonia after an ILI episode caused by HPIV
infection.
ARI and JIA flares
During the study 50 JIA flares or worsening of JIA activ-
ity parameters were observed in 44/70 patients included
in at least one of two surveillance periods, and 10 of
them (20%) were temporally associated with respiratory
infection episodes (7 classified as ILI). In 8 of those epi-
sodes we could not identify any other triggering factor
possibly associated with the flare (Table 3).
The possible factors associated with the 40 JIA flare
episodes not related to respiratory infections were sus-
pension or nonadhearance to medication in twelve epi-
sodes, and intercurrent infections in seven episodes:
otitis, chickenpox, parotiditis (2), gastroenterocolitis (2)
and infection sacroiliitis. In twelve-one episodes there
were no identifiable causes for the flares.
There was no significant difference in the total number
of flares related to gender, age (< 9 years old and ≥ 9 years
old), JIA type of onset (oligoarticular, polyarticular or sys-
temic), use of immunosuppressive therapy, period of sur-
veillance (SV1 or SV2) or administration of influenza
vaccine. Flares or worsening of JIA activity parameters
associated with ARI were more frequently observed in
patients with systemic JIA (5 of the 16 flares that oc-
curred in this group) as compared to patients with
polyarticular JIA (2/14 flares, p = 0.03).
Response to influenza vaccine
Pre-vaccination geometric mean titers (GMT) with 95%
confidence interval (95% CI) for H1N1, H3N2 and B/
Florida in JIA patients were 13.3 (11-21.5), 12.4 (10.5-21)
and 14.1 (12.2-23.3) respectively; and 43.4 (41.7-46.5), 33.2
(31.5-38.7) and 33.6 (31.9-37.6) in post vaccine period.
Vaccine response of the patients and controls is described
in Table 4.
Thirty-one of 44 patients (70%) who received influenza
vaccine were using methotrexate or leflunomide, one pa-
tient was on cyclosporine, and five were receiving anti-
TNF.alpha; drugs at the time of vaccination. Six patients
were using corticosteroids at mean daily dose of 0.3
(0.1-0.6) mg/kg/day, with mean duration of treatment of
16.8 (10-24) months.
In general, response to influenza vaccine was not
influenced by age, JIA type of onset, therapeutic re-
gimens or disease activity. Patients on anti-TNFα drugs
presented lower seroconversion (p = 0.03) and sero-
Table 3 Temporal association between acute respiratory infections and reactivation or worsening of JIA activity
parameters in 10 of 70 patients who participated in the epidemiological surveillance 1 and/or 2 for respiratory virus
Vírus
detected
ARI Onset
type
Signs of disease worsening or flare Temporal relationship Therapeutic decision
RSVA NILI** S 10% increase in the number of active joints, 50%
worsening of the patient’s subjective evaluation
Concomitant Increase the dose of
cyclosporine
HAdv ILI*** S 60% increase in the number of active joints and
200% worsening of the patient’s subjective
evaluation
3 weeks Intra-articular infection
HPIV1 ILI S Flare# Concomitant None. Symptoms improved
with resolution of Flu-like
symptoms
NC* ILI S Flare 5 days Increase the dose of
methotrexate and oral
prednisone course
HPIV3 ILI S Flare with systemic symptoms 7 days Pulse of prednisone
HAdv ILI O Flare 12 days Restart methotrexate
NC NILI P 200% increase in number of active joints and 50%
increase in ESR
7 days Start nonsteroidal
antiinflammatory
RSVA/
HMPV
NILI P Flare Concomitant Increase prednisone dose
Flu A ILI P Worsening of morning stiffness and joint effusion.
Appearance of cysts on wrists.
Concomitant Start etanercept and
leflunomide
Confounding factor: varicella
8 days before
NC ILI S Flare 1 week Confounding factor:
methotrexate suspended 30 days
before
Pulse of prednisone
Restart methotrexate
Flu: Influenza virus A and B, HRSV: respiratory syncytial virus A and B, HMPV: metapneumovirus, HPIV: parainfluenza virus 1 and 3, HBov: bocavirus, HAdv:
adenovirus, HRV: rhinovirus, HCov: coronavirus OC43 and 229E. O: oligoarticular, P: polyarticular, S: systemic *NC: not collected. **NILI: ARI not Flu-like. ***ILI: Flu-
like illness # Flare: defined as worsening by 40% in two or more of the six ACRPed criteria with simultaneous improvement of up to one criterion above 30%.
Surveillance 1: from March to August 2007. Surveillance 2: from March to August 2008, influenza vaccine was given in this period.
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protection (60%) responses to H1N1 strain, but the
seroprotection above the cut-off levels to the other
strains: H3N2 (100%) and B/Florida (80%).
The vaccine was considered safe. Pain at the injection
site was described in 6/44 (13.6%) JIA patients and 1/10
(10%) healthy children; other local changes (redness and
swelling or warmth) were reported by 2/44 (4.5%) of JIA
patients and in 1/10 healthy children. Six patients devel-
oped cough and rinorrhea, without fever, during the first
ten days after receiving the vaccine.
No significant differences were found in JIA activity
index (ACRPed30) or doses of prednisone used by pa-
tients before and after 30, 90 and 180 days of vaccin-
ation (p = 0.22), Table 5. Methotrexate weekly dose was
significantly lower 30 and 90 days after vaccination when
compared to the pre vaccination dose (p = 0.03).
No patient reported ILI symptoms during the 6-month
post-vaccine follow-up period.
Discussion
As far as we know there are no published studies that
evaluating the frequency and impact of ARI and ILI in
JIA patients.
The observed attack rate of 7.6 and 3.9 ARI per 1000
child-days in 2007 and 2008, respectively, was similar to
ARI rates previously reported in healthy children in the
same age [37]. Viral agents were detected in 60% of 33
episodes sampled during the study, and influenza and
HRV were the most frequently detected viruses. In stud-
ies conducted in tropical countries, when HRV was
tested, it was the most frequently identified virus, and
influenza detection ranged from 1 to 32% of positive
samples. The differences in study design and virus detec-
tion assays may explain differences in frequencies of
virus detection [17,18,38,39].
Viral dual infections were detected in 15% of positive
samples in our study and HRV was identified in 75% of
them. Co-infections were also detected in other studies,
ranging from 9.5 to 81% of positive samples [39-41].
Evaluating only ILI episodes, corresponding to 26.6%
of ARI episodes, influenza was the most frequently
detected virus (25%), but HPIV (1 and 3) and HAdv
were also detected. Other studies have also called atten-
tion to the fact that not only influenza is detected in ILI
episodes. In Brazil, a study showed that 57% of ARI epi-
sodes were classified as ILI and influenza accounted for
only 31% of them, with HRV being detected in 19.6% of
ILI episodes [17]. Therefore, it is difficult to estimate
influenza vaccine efficacy based only on the clinical ana-
lysis of ILI episodes.
The frequency and clinical pattern of ARI in patients
with chronic disease have been poorly studied. Respira-
tory viruses were detected in 61 of 148 febrile episodes
that occurred in 51 children with leukemia [42] and the
frequency of ARI in 20 children with cystic fibrosis and
18 controls during a 6-month surveillance period was
similar, but the morbidity of these infections was higher
in patients with cystic fibrosis [43]. In our study, viral in-
fections, including influenza infection, had a satisfactory
outcome in JIA patients. Only one patient had acute oti-
tis media and pneumonia associated with HPIV.
Despite the outcome of viral infections in our study
being similar to the healthy population, the results
suggest that viral ARI and ILI may be associated with
JIA exacerbations or flares. Of 50 episodes of flares or
worsening of disease activity observed during the
study period, ten happened along with or within 3 -
weeks of a viral ARI. HRSV, HAdv, HPIV, HMPV
and influenza were the viruses detected in associ-
ation with these flares.
Table 4 Strain-specific A/Salomon Islands/3/2006 (H1N1), A/Brisbane/10/2007 (H3N2) and B/Florida/4/2006 (B/Florida)
hemagglutination inhibition titers, seroconversion factor, seroconversion rate, and seroprotection rate
H1N1 H3N2 B/Florida
Day 0 Day 30 Day 0 Day 30 Day 0 Day 30
Seroprotection ratea (%)
JIA (44) 21/43 (48.8) 44(100) 20/43 (46.5) 40(91) 20/43 (46.5) 42(95)
Healthy children# (10) 7(70) 10(100) 6(60) 8(80) 5(50) 10(100)
Seroconversion rateb (%)
JIA 40/43(93) 32/43 (74.4) 31/40 (77.5)
Healthy children 7/7(100) 3/8 (37.5) 6/8 (75)
Seroconversion factorc
JIA 16.5 5.2 7.2
Healthy children 9.8 3.0 4.0
To meet the Committee for Proprietary Medicinal Products (CPMP) guidelines each of the vaccine antigens must meet at least one of the following criteria:
seroprotection rate exceeding 70%, seroconversion rate exceeding 40%, and seroconversion factor exceeding 2.5. a Seroprotection rate: the percentage of vaccine
recipients with a serum HI titres of at least 1:40 after vaccination. bSeroconversion rate: the percentage of vaccine recipients with an increase in serum HI titres by
at least a factor of 4 after vaccination. c Seroconversion fator: the fold increase in serum geometric mean HI titres after vaccination.
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Few studies have addressed the possible relationships
of viral ARI and JIA [3,4]. Recently, Toplak et all re-
ported a JIA relapse after an ILI episode [12].
In the present study, 21 of the 50 JIA flares or worsen-
ing of JIA activity parameters (42%) were not temporally
associated with any know triggers. In this way, it is impos-
sible to determine whether there was a coincidental or
causal relationship between ARI and JIA flares, but we can
speculate that ARI may have had a role in 20% these wors-
ening episodes. Another interesting finding of our study is
that the majority of flares associated with viral infections
occurred in patients with systemic onset JIA.
We have also assessed the safe, immunogenicity and
effectiveness of influenza vaccine.
Prospective open-cohort studies suggest that influenza
vaccination was safe [5-11], with no association with dis-
ease activity or autoantibodies induction [12]. In our
study, patients were followed for a 6-month period after
vaccination and no significant side occurred, including
flares of the disease.
The immunogenicity of influenza vaccine in JIA pa-
tients has been previously looked at [5,6,8-12].
Malleson et al evaluated the immunogenicity of influ-
enza vaccine in 34 children with chronic arthritis and in
13 healthy controls and no differences in antibody titers
after vaccination were observed between children with
chronic arthritis and controls, nor among patients trea-
ted with DMARDS and/or prednisone [6].
Kanadoudi-Tsakalidou et al evaluated 49 JIA patients,
and also showed satisfactory vaccine immunogenicity
and effectiveness with no ILI episode observed in a six-
month period after the vaccine [5].
Ogimi et al evaluated 23 children with JIA and found
no difference in seroconversion rates when compared
gender, age, vaccine dosage, prednisolone dosage or use
of other immunosuppressant by logistic regression ana-
lysis. That study was the first to evaluate influenza
vaccine seroconversion in one patient with JIA under
treatment with anti-TNF [8].
The immunogenicity and safety of epidemic influenza
A H1N1/2009 vaccine were studied in 237 patients with
autoimmune rheumatic disease (ARD), 93 JIA, and in 91
healthy controls. The authors demonstrated a reduced
immune response to this vaccine in ARD patients when
compared to controls and found glucocorticoid use as
the major factor for decreased antibody production [9].
The immunogenicity of influenza vaccine was recently in-
vestigated in 27 patients with systemic-onset juvenile idio-
pathic arthritis receiving tocilizumab, an anti-interleukin-6
receptor antibody. The authors observed that high-dose
prednisolone, but not tocilizumab, impaired the production
of influenza antibodies in these patients [11].
Toplak et all recently showed adequate response to
influenza vaccine in JIA patients, except in a subgroup
of 4 children receiving anti-TNF therapy, and observed
no difference in the rate of influenza infection between
31 JIA patients and 14 healthy children followed for 6 -
months after vaccination [12].
In our study the immunogenicity of influenza vaccine
was found to be satisfactory. We found no influence of
age, JIA type of onset, activity of disease, use of prednis-
olone or methotrexate in seroconversion rates. Only the
subgroup of patients using anti TNF alpha showed lower
seroconversion rate for the H1N1 strain. As the sample
size in the present study is small, it was not possible to
assess the adjusted odds ratio of using anti-TNF alpha in
relation to other variables. A study with children with
inflammatory bowel disease showed that patients receiv-
ing anti-TNF therapy were less likely to be seroprotected
against B strain [44].
Dell’Era et al recently evaluated if the administration
of the more immunogenic adjuvanted influenza vaccine
(MF59-adjuvanted seasonal vaccine) could overcome the
problem of the possibly impaired antibody production in
60 JIA patients (30 treated with etarnecept). The safety
and tolerability of the vaccine were satisfactory, but the
results of this study indicate a reduced immune response
to this vaccine in JIA children and adolescents treated with
etanercept in comparison with those with DMARDs and
healthy controls [10].
This was the first study that assessed the effectiveness of
influenza vaccine thorough the surveillance of vaccinated
Table 5 Parameters considered for JIA activity index (ACRPed30) of 44 JIA patients before and 30, 90 and 180 days
after vaccination
Pré Mean (SD) 30 90 180 p*
Number of joints with active arthritis 1.4(2.4) 1.2(2.0) 1.1(1.7) 1.7(4.5) 0.39
Number of joints with limited range of motion 2.2(4.7) 2.2 (4.8) 2.3(5.1) 1.7(4.4) 0.96
Physician’s global assessment of disease activity (0-10) 1.3(1.4) 0.85(1.2) 0.92(1.4) 0.8(1.6) 0.65
Parent/patient assessment of overall well being (0-10) 1.3(1.8) 1.1(1.85) 1(1.5) 0.88(1.7) 0.76
CHAQ 0.2(0.5) 0.12(0.3) 0.05(0.2) 0.03(0.12) 0.29
ESR (mm/hour) 12.9(8.6) 14.6(10.2) 13(9.2) 12.1(9.3) 0.75
ESR, Erythrocyte sedimentation rate; ACRPed30, JIA activity index -Pediatric American College of Rheumatology 30%; CHAQ, Childhood Health Assessment
Questionnaire.* Nonparametric Friedman test.
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and unvaccinated patients during the influenza seasonal
periods and there was no significant difference in the
frequency of ARI episodes after the vaccination. Episodes
classified as ILI were more common in unvaccinated pa-
tients, but this difference was not maintained after adjusting
for other covariates such as surveillance period, age, im-
munosuppressant use and active disease. We believe that
the failure to maintain significance of IL1 episodes in vacci-
nated patients is related to the small sample size since we
did not identify any specific covariate responsible to this
failure when we performed the multiple model analysis.
Thus, it is not possible to prove that the vaccine was really
effective against influenza infections, as the pattern or
seasonality of influenza infections seemed to be different
between the two surveillance periods. However, it is
important to state that during the follow-up period of
six months after vaccination, none of the vaccinated
patients had ILI episodes.
Conclusion
Infections caused by common respiratory viruses may be
associated with JIA flares, a hypothesis to be addressed
in further, larger epidemiological studies. Trivalent split
influenza vaccine seems to be immunogenic, safe and ef-
fective in children and adolescents with JIA, despite the
use of immunosuppressive agents or activity of the
disease. Studies of larger numbers of patients treated
with TNFα blockers are necessary in order to verify
whether a lower vaccine response occurs in this group
of patients.
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